on this page
Developing a new drug for human use is a lengthy and costly process that takes an average of 10 years or more and costs approximately $2.6 billion. Yet, when one considers the number of people a successful drug can help, the return on investment can be astounding.
Before a drug goes to market, its efficacy, safety, and mechanism of action (MOA) must be thoroughly understood. Animal models for research work to minimize adverse side effects and maximize therapeutic properties of a drug before it is taken to clinical trials. Biocytogen is a one-stop CRO that provides humanized mouse models for immuno-oncology and autoimmune/inflammatory disease targets, which can help move projects from target to IND application.
Due to species differences, wild-type mice often fail to accurately evaluate human-specific drugs. At Biocytogen, we have developed drug target humanized mouse models—one of the most versatile animal models for in vivo evaluation. These in vivo models are created by replacing mouse genes with their human counterparts, allowing drug candidates to interact with humanized targets. This enables precise in vivo assessments of drug efficacy, toxicity, and pharmacokinetics & pharmacodynamics (PK&PD), providing a reliable foundation for translational research.
Targets of our humanized mouse models cover immune-checkpoint, tumor microenvironment (TME) modulators and tumor-associated antigens (TAA) for oncology research,cytokines/cytokine receptors and other biomarkers related to autoimmune and inflammatory diseases, as well as metabolic and neurological disorders.
Using the advanced gene editing platform, our experts team professionally designs the genetic modifications in target humanized mice. These genetically humanized mice exhibit expression profiles similar to humans, ensuring that humanized genes do not interfere with the mice's signaling pathways or functions.
Our animal models have comprehensive validation data, including genotypic and phenotypic analysis, functional assays and in vivo studies.
Supported by a high-quality animal center, we provide large-scale breeding services that minimize variation among individual mice and experimental batches. This ensures consistency and reliability in preclinical studies, contributing to more robust and reproducible research outcomes.
Our animal models are independently developed and fully owned by us, holding independent intellectual property rights, which provide clients with reliable and secure research tools that ensure the integrity and reproducibility of experimental data.
Biocytogen has been serving customers around the world, both in academia and industry, for over a decade. With our commitment to quality in everything we do, we'll work closely with you to deliver models and services that meet your precise specifications in a timely manner. We offer world-leading, cutting-edge technology platforms, superior service, a fast timeline, a large collection of animal models for research and a 100 percent satisfaction guarantee.
We have established a world-class animal model production center, including three animal faculties encompassing a total of approximately 55,000 sq. m., with an annual supply capacity of 800,000 gene-edited mice. Shipping is available to our customers worldwide.
Contact us today to learn how Biocytogen’s humanized mouse models and humanized cell lines can accelerate your preclinical research.